Analytical Data
-
Gene name
SIGLEC10
- Application
-
Alternative Names
PRO940; SLG2; Sialic Acid Binding Ig-Like Lectin 10 Ig-Like Lectin 7; Siglec-Like Gene 2
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96LC7
-
Expression Region
Met571~Gln697
-
Molecular Weight
17kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Siglec-10, or sialic acid-binding immunoglobulin-like lectin 10, is a member of the Siglec family of receptors, which are predominantly expressed on immune cells. These receptors play crucial roles in regulating immune responses and maintaining self-tolerance by recognizing sialic acid-containing glycoproteins and glycolipids. Over the years, research has shown that Siglec-10 is involved in modulating processes like inflammation, apoptosis, and the immune response to infections and cancer. Given its regulatory function, Siglec-10 has attracted attention as a potential therapeutic target for various diseases, including autoimmune disorders and cancers. Recombinant Siglec-10 proteins have been developed for use in research to better understand their structure, ligand interactions, and biological functions. Additionally, the application of recombinant technology enables the production of these proteins in sufficient quantities for high-throughput studies and potential therapeutic applications. Ongoing studies aim to elucidate the signaling pathways mediated by Siglec-10, its role in cell-cell interactions within the immune microenvironment, and its potential as a biomarker for disease progression. Understanding the mechanisms underlying Siglec-10 function may provide valuable insights that lead to the development of novel immunotherapies and approaches for modulating immune responses in various clinical settings.
